Lamivudine/raltegravir

Lamivudine/raltegravir
Combination of
LamivudineReverse-transcriptase inhibitor
RaltegravirIntegrase inhibitor
Clinical data
Trade namesDutrebis
Routes of
administration		Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.[1] It contains lamivudine and raltegravir. It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1][2]

Lamivudine/raltegravir is not available in the United States.[3]

References

  1. ^ a b c d "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.
  2. ^ "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.
  3. ^ "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.